Eurofins-Cerep SA
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company's research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and… Read more
Eurofins-Cerep SA (ALECR) - Total Liabilities
Latest total liabilities as of June 2025: €11.04 Million EUR
Based on the latest financial reports, Eurofins-Cerep SA (ALECR) has total liabilities worth €11.04 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eurofins-Cerep SA - Total Liabilities Trend (2000–2024)
This chart illustrates how Eurofins-Cerep SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Eurofins-Cerep SA Competitors by Total Liabilities
The table below lists competitors of Eurofins-Cerep SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nextensa NV
BR:NEXTA
|
Belgium | €815.25 Million |
|
OPTIMIZERx Corp
NASDAQ:OPRX
|
USA | $48.06 Million |
|
Q2 Metals Corp.
OTCQB:QUEXF
|
USA | $5.66 Million |
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
Turkey | TL1.89 Billion |
|
TCM Group
CO:TCM
|
Denmark | Dkr695.20 Million |
|
The Phoenix Holdings Ltd.
TA:PHOE
|
Israel | ILA177.74 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Eurofins-Cerep SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eurofins-Cerep SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eurofins-Cerep SA (2000–2024)
The table below shows the annual total liabilities of Eurofins-Cerep SA from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €12.32 Million | -15.79% |
| 2023-12-31 | €14.63 Million | +3.65% |
| 2022-12-31 | €14.12 Million | -1.63% |
| 2021-12-31 | €14.35 Million | +31.08% |
| 2020-12-31 | €10.95 Million | +5.12% |
| 2019-12-31 | €10.42 Million | +3.20% |
| 2018-12-31 | €10.09 Million | +13.76% |
| 2017-12-31 | €8.87 Million | +4.56% |
| 2016-12-31 | €8.49 Million | -16.91% |
| 2015-12-31 | €10.21 Million | +4.88% |
| 2014-12-31 | €9.74 Million | -33.03% |
| 2013-12-31 | €14.54 Million | -11.07% |
| 2012-12-31 | €16.35 Million | -14.65% |
| 2011-12-31 | €19.16 Million | -13.96% |
| 2010-12-31 | €22.26 Million | -12.37% |
| 2009-12-31 | €25.41 Million | -24.02% |
| 2008-12-31 | €33.44 Million | -13.86% |
| 2007-12-31 | €38.81 Million | -37.64% |
| 2006-12-31 | €62.25 Million | +18.53% |
| 2005-12-31 | €52.52 Million | +65.01% |
| 2004-12-31 | €31.83 Million | +47.48% |
| 2003-12-31 | €21.58 Million | +17.33% |
| 2002-12-31 | €18.39 Million | +24.89% |
| 2001-12-31 | €14.73 Million | +25.88% |
| 2000-12-31 | €11.70 Million | -- |